Champions Oncology Q4 revenue rises; margin improves driven by cost discipline

Overview

• US oncology research provider's fiscal Q4 revenue rose 12% yr/yr to $13.8 mln

• Company posted positive adjusted EBITDA and adjusted EPS of $0.01 for the quarter

• Improved margins driven by cost discipline and in-house radiopharmaceutical transition

Outlook

• Company did not provide specific guidance for future quarters or fiscal year

Result Drivers

• COST DISCIPLINE - Co said lower outsourced research services expenses and compensation reduced cost of revenue, supporting higher margins

• IN-HOUSE TRANSITION - Co said moving certain radiopharmaceutical activities in-house lowered costs and improved margins

• STRATEGIC INVESTMENTS - Co continued to invest in commercial organization and data platform, increasing operating expenses

Company press release: ID:nACSVT9lsa

Key Details

Analyst Coverage

• The stock recently traded at 59 times the next 12-month earnings vs. a P/E of 56 three months ago

Reuters Recommended Reads

• July 27 - AstraZeneca drug prices evolving in response to Trump policy, executive says

• July 27 - Sarepta names former Abbvie president as CEO as Ingram retires

• July 24 - FDA advisers recommend relaxing US rules on compounding peptides

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)